Insulet (PODD) Stock Looks Reasonable Even After A 57% Fall

Insulet stock has fallen sharply over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiple checks currently point to a stock that screens as undervalued, which gives investors a pricing puzzle to unpack.

• Over the past 12 months, Insulet shares have declined 57.3%, which puts recent price action well behind many large healthcare peers and raises questions about whether sentiment has become too pessimistic.
• Investor focus is now on how Insulet can convert demand for its diabetes devices into durable cash flows, while weaker utilization and retention among some type 2 diabetes customers highlight the risk that growth may prove less consistent than hoped.
• Across the broader valuation checks, Insulet scores a 4 out of 6 on value, which is a mixed picture rather than a clear bargain or clear overvaluation and suggests investors need to look closely at the underlying assumptions in the intrinsic value and multiple based views.

The stock's next move may depend on whether Insulet's current share price already reflects the concerns around type 2 customer trends or whether the intrinsic value case and multiple signals are pointing to a gap that could close over time.

Compare Insulet's recent 57.3% one year share price decline and current undervalued signals with a curated set of high quality stocks that also screen as potentially mispriced using the 45 high quality undervalued stocks.

Does Insulet Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Insulet could be worth based on its future cash generation discounted back to today.

For Insulet, the model starts with latest twelve month free cash flow of about $313.2 million and then applies a growing cash flow path using a 2 stage Free Cash Flow to Equity approach. Based on these assumptions, the intrinsic value is estimated at about $245.61 per share in dollar terms. This estimate is well above the current share price and implies the stock trades at a 40.9% discount. Despite the recent Q2 2026 update noting weaker utilization and retention among some type 2 diabetes customers, the market price remains well below what this cash flow view suggests.

On this Discounted Cash Flow view, Insulet stock currently screens as undervalued relative to its estimated intrinsic value.

Our Discounted Cash Flow (DCF) analysis suggests Insulet is undervalued by 40.9%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Insulet.

Is Insulet a Bargain on Earnings?

The P/E multiple suits Insulet because investors often look at earnings when judging profitable medical equipment companies. Insulet currently trades on a P/E of about 26.8x, which is close to the Medical Equipment industry average of 26.7x. On that simple comparison, the stock does not look especially cheap or expensive relative to the broader group.

However, the more tailored fair P/E ratio for Insulet is calculated at about 30.4x, based on its specific mix of growth, margins, size and risk. That is higher than the current 26.8x, which means the stock trades at a discount to the level implied by this framework even though the peer average sits higher at roughly 38.0x. Taken together, this suggests Insulet may be undervalued on an earnings basis when compared with both the custom fair multiple and the broader peer set.

On the P/E multiple, Insulet stock appears undervalued relative to both its modelled fair ratio and similar medical equipment peers.

See what the numbers say about this price — find out in our valuation breakdown.

The Insulet Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Insulet's valuation puzzle leaves off. They spell out what future growth, margins and earnings would need to look like for the stock to be worth materially more or less than today's price on the Community page. Each one turns its view of fair value into a specific thesis about Insulet's business that you can revisit over time and judge against how the story actually plays out.

Community views on Insulet are split between a reset opportunity and a reset warning, with very different stories attached to the same numbers.

Bull case: 36% undervalued

"Broad U.S. pharmacy access with coverage for more than 90% of insured lives and presence in about 48,000 pharmacies, combined with a pay as you go model with typical user costs around US$1 a day, reduces friction to start and stay on therapy..."

Read the full Bull Case to see why Insulet could be undervalued

Bear case: roughly fairly valued

"Several downgrades to Neutral, Hold, Equal Weight, Market Perform and Perform point to rising caution that type 2 diabetes attrition, softer utilization and U.S. growth guidance reset could pressure execution and limit upside on the stock..."

Read the full Bear Case to see why Insulet could be overvalued

Do you think there's more to the story for Insulet? Head over to our Community to see what others are saying!

The Bottom Line

For Insulet, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple view currently point in the same direction and suggest the stock screens as undervalued rather than stretched. The key question is whether the discount reflects temporary worry around type 2 utilization and retention or a more lasting reset in what the business can earn. What matters from here is whether Insulet can turn its installed base and pharmacy access into steadier cash flows from type 2 users. If that proves harder than hoped, the current discount may be less a bargain and more the market pricing in execution risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com